Gene Therapy

Principles and Applications

  • Thomas Blankenstein

Table of contents

  1. Front Matter
    Pages I-XII
  2. Introduction

    1. K. Sikora
      Pages 1-10
  3. Gene Transfer Methods

    1. Front Matter
      Pages 11-11
    2. P. D. Robbins
      Pages 13-28
    3. E. Wagner
      Pages 47-59
    4. O. Bagasra, M. Amjad, M. Mukhtar
      Pages 61-71
    5. M. Hallek, C.-M. Wendtner, R. Kotin, D. Michl, E.-L. Winnacker
      Pages 73-91
    6. H. Tahara, T. Kitagawa, T. Iwazawa, M. T. Lotze
      Pages 93-102
  4. Gene Therapy of Single Gene Defects

    1. Front Matter
      Pages 103-103
    2. A. Aiuti, C. Bordignon
      Pages 105-121
    3. D. J. Porteous, J. A. Innes
      Pages 137-149
    4. G. Cichon, M. Strauss
      Pages 151-167
  5. Gene Marking

    1. Front Matter
      Pages 169-169
    2. K. Cornetta, E. F. Srour, C. M. Traycoff
      Pages 171-187
    3. C. Bonini, C. Bordignon
      Pages 189-199
    4. T. Licht, M. M. Gottesman, I. Pastan
      Pages 201-213
  6. Gene Therapy of Cancer

    1. Front Matter
      Pages 215-215
    2. R. G. Vile
      Pages 247-266
    3. F. Cavallo, P. Nanni, P. Dellabona, P. L. Lollini, G. Casorati, G. Forni
      Pages 267-282
    4. S. Cayeux, Z. Qin, B. Dörken, T. Blankenstein
      Pages 283-298
    5. E. Nößner, D. J. Schendel
      Pages 299-312
    6. R. E. M. Toes, F. Ossendorp, E. I. H. van der Voort, E. Mengedé, R. Offringa, C. J. M. Melief
      Pages 349-355
  7. Back Matter
    Pages 373-380

About this book


K. Sikora Gene therapy is one of the fastest developing areas in modern medical research. Transcending the classical preclinical and clinical disciplines, it is likely to have far­ reaching consequences in the practice of medicine, as we enter the next millennium. Currently, there are over 200 seperate active clinical trials with over 2,500 patients entered. These studies involve over 20 countries and include patients with a wide range of diseases, including cancer, HIV infection; cystic fibrosis (CF), haemophilia, diabetes, immune deficiencies, metabolic disorders, ischaemic heart disease and arthritis. Gene therapy can be defined as the deliberate transfer of DNA for therapeutic purposes. There is a further implication that only specific sequences containing rel­ evant genetic information are used; otherwise, transplantation procedures involving bone marrow, kidney or liver could be considered a form of gene therapy. The con­ cept of transfer of genetic information as a practical clinical tool arose from the gene-cloning technology, developed during the 1970s. Without the ability to isolate and replicate defined genetic sequences, it would be impossible to produce purified material for clinical use. The drive for the practical application of this technology came from the biotechnology industry with its quest for complex human biomole­ cules produced by recombinant techniques in bacteria. Within a decade, pharma­ ceutical-grade insulin, interferon, interleukin 2 and tumour necrosis factor were all involved in clinical trials. The next step was to obtain gene expression in vivo.


DNA HIV bacteria biotechnology cancer gene expression gene therapy genes

Editors and affiliations

  • Thomas Blankenstein
    • 1
  1. 1.Max-Delbrück-Centrum für molekulare MedizinBerlin-BuchGermany

Bibliographic information

Industry Sectors
Chemical Manufacturing
Consumer Packaged Goods